Research
Hormonal
GLP-1RA use was associated with a lower risk of major adverse cardiovascular events (MACE) in nondiabetic patients with PAD (HR: 0.61; 95% CI: 0.57–0.66; p < 0.001).
GLP-1RAs may be beneficial for reducing cardiovascular risks in patients with PAD who do not have diabetes.
StrongSupportsmedium confidence
GLP-1RA use was associated with lower risk of MACE (hazard ratio (HR): 0.61; 95% confidence interval (CI): 0.57–0.66; p < 0.001).
Why this rating
Based on a large retrospective cohort study design.
Source
Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis
Emmanuel Daniel et al. · Journal of Investigative Medicine · 2025
cohort · n=27110Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →